Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

41.40 +0.92 (+2.27%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Flexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise Therapeutics ↗

May 01, 2023

Truist initiated coverage on Edgewise Therapeutics Inc (NASDAQ: EWTX) with a Buy rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday ↗

April 25, 2023

U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Recap: Edgewise Therapeutics Q2 Earnings ↗

August 04, 2022

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)

March 30, 2023

From Edgewise Therapeutics

Via Business Wire

Top 5 Health Care Stocks That Preparing To Pump This Quarter ↗

March 29, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

March 21, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference

March 14, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

March 06, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023

March 01, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology

February 28, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 23, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023

February 07, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

January 04, 2023

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023

December 21, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

December 20, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

November 09, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Reports Third Quarter 2022 Financial Results

November 03, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

October 27, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

October 13, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society

October 06, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 16, 2022

From Edgewise Therapeutics, Inc.

Via Business Wire

Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday ↗

September 16, 2022

Gainers

Via Benzinga

Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

September 13, 2022

From Edgewise Therapeutics

Via Business Wire

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Edgewise Therapeutics Announces Proposed Offering of Common Stock

September 13, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

September 11, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)

September 07, 2022

From Edgewise Therapeutics

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.